Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF

Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF

Abstract Aims This study sought to assess the effect of treatment of sacubitril/valsartan (S/V) on improving cardiac function and reversing cardiac remodelling in patients with acute coronary syndrome (ACS) complicated with heart failure with reduced ejection fraction after percutaneous coronary int...

Full description

Bibliographic Details
Main Authors:	Henan Liu, Yongkang Su, Jian Shen, Yang Jiao, Ying Li, Bing Liu, Xiaoling Hou, Qinhua Jin, Yundai Chen, Zhijun Sun, Qing Xi, Bin Feng, Zhenhong Fu
Format:	Article
Language:	English
Published:	Wiley 2024-04-01
Series:	ESC Heart Failure
Subjects:	Sacubitril/valsartan Acute coronary syndrome Percutaneous coronary intervention Heart failure with reduced ejection fraction
Online Access:	https://doi.org/10.1002/ehf2.14646

Similar Items

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
by: Iacopo Fabiani, et al.
Published: (2023-10-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
by: Pei Yang, et al.
Published: (2023-01-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction
by: Fan H, et al.
Published: (2023-02-01)

The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
by: Kyeong‐Hyeon Chun, et al.
Published: (2020-12-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)
by: Lamyaa Elsayed Allam, et al.
Published: (2024-03-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Long-Term Effects of Sacubitril-Valsartan on Cardiac Remodeling: A Parallel Echocardiographic Study of Left and Right Heart Adaptive Response
by: Federica Valli, et al.
Published: (2023-04-01)

Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF
by: Massimo Iacoviello, et al.
Published: (2024-02-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan
by: Valentina Mantegazza, et al.
Published: (2021-10-01)

Does sacubitril/valsartan work in children with heart failure?—a pilot study
by: Yahe Xu, et al.
Published: (2023-11-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2020-09-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan
by: Michele Correale, et al.
Published: (2023-01-01)

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
by: Chih‐Yuan Niu, et al.
Published: (2022-09-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)

The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
by: Ying Zhao, et al.
Published: (2022-07-01)

Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis
by: Qian Xiang, et al.
Published: (2022-04-01)

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024-03-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)